{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:15:04Z","timestamp":1788322504113,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00277-024-05677-0","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T22:01:35Z","timestamp":1709330495000},"page":"1717-1727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-7885","authenticated-orcid":false,"given":"Santiago","family":"Mercadal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina M.","family":"Odstrcil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Couriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"issue":"4","key":"5677_CR1","doi-asserted-by":"publisher","first-page":"30040","DOI":"10.1016\/j.hemonc.2017.05.004","volume":"10","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M (2017) Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. Hematol Oncol Stem Cell Ther 10(4):30040\u201330047. https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.004","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"5677_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"5677_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"5677_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.771","author":"P Dreger","year":"2020","unstructured":"Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M et al (2020) Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation? Biol Blood Marrow Transplant. https:\/\/doi.org\/10.1016\/j.bbmt.2019.12.771","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"5677_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"AJ Peniket","year":"2003","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, De Witte T et al (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31(8):667\u2013678. https:\/\/doi.org\/10.1038\/sj.bmt.1703891","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5677_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2013.09.012","volume":"42","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN et al (2014) Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Exp Hematol 42(1):39\u201345. https:\/\/doi.org\/10.1016\/j.exphem.2013.09.012","journal-title":"Exp Hematol"},{"issue":"11","key":"5677_CR7","doi-asserted-by":"publisher","first-page":"613954","DOI":"10.3389\/fimmu.2020.613954","volume":"2","author":"A Tomaszewska","year":"2021","unstructured":"Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E et al (2021) Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: EBMT registry analyses following allogeneic stem cell transplantation for B-cell malignancies. Front Immunol 2(11):613954. https:\/\/doi.org\/10.3389\/fimmu.2020.613954","journal-title":"Front Immunol"},{"issue":"7","key":"5677_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","volume":"20","author":"BL McClune","year":"2014","unstructured":"McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY et al (2014) Allotransplantation for patients age \u226540 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 20(7):960\u2013968. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"5677_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2017.03.031","volume":"23","author":"A Dodero","year":"2017","unstructured":"Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Lori A et al (2017) Allogeneic stem cell transplantation for relapsed\/refractory B cell lymphomas: results of a multicenter phase II prospective trial including rituximab in the reduced-intensity conditioning regimen. Biol Blood Marrow Transplant 23(7):1102\u20131109. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.031","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"5677_CR10","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E Elm","year":"2014","unstructured":"Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2014) STROBE initiative. Int J Surg 12(12):1495\u20131499. https:\/\/doi.org\/10.1016\/j.ijsu.2014.07.013","journal-title":"Int J Surg"},{"issue":"2","key":"5677_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","volume":"174","author":"TS Fenske","year":"2016","unstructured":"Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q et al (2016) Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 174(2):235\u2013248. https:\/\/doi.org\/10.1111\/bjh.14046","journal-title":"Br J Haematol"},{"issue":"1","key":"5677_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","volume":"16","author":"HM Lazarus","year":"2010","unstructured":"Lazarus HM, Zhang MJ, Carreras J, Lattin BM, Ataergin AS, Bitran JD et al (2010) A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 16(1):35\u201345. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"5677_CR13","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","volume":"120","author":"U Bacher","year":"2012","unstructured":"Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al (2012) Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 120(20):4256\u20134262. https:\/\/doi.org\/10.1182\/blood-2012-06-436725","journal-title":"Blood"},{"issue":"5","key":"5677_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al (2013) Impact of pre transplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 19(5):746\u2013753. https:\/\/doi.org\/10.1016\/j.bbmt.2013.01.024","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5677_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bmt.2015.286","volume":"51","author":"SP Robinson","year":"2016","unstructured":"Robinson SP, Boumendil A, Finel H, Blaise D, Poir\u00e9 X, Nicolas-Virelizier E et al (2016) Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 51(3):365\u201371. https:\/\/doi.org\/10.1038\/bmt.2015.286","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"5677_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ Kampen","year":"2011","unstructured":"Kampen RJ, Canals C, Schouten HS, Nagler A, Thomson KJ, Vernant JP et al (2011) Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29(10):1342\u20131348. https:\/\/doi.org\/10.1200\/JCO.2010.30.2596","journal-title":"J Clin Oncol"},{"issue":"6","key":"5677_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","volume":"91","author":"L Rigacci","year":"2012","unstructured":"Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al (2012) Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 91(6):931\u2013939. https:\/\/doi.org\/10.1007\/s00277-011-1395-9","journal-title":"Ann Hematol"},{"issue":"8","key":"5677_CR18","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41409-021-01264-3","volume":"56","author":"L Bento","year":"2021","unstructured":"Bento L, Guti\u00e9rrez A, Novelli S, Montoro J, Pi\u00f1ana JL, L\u00f3pez-Corral L et al (2021) Allogeneic stem cell transplantation as a curative option in relapse\/refractory diffuse large B cell lymphoma: Spanish multicenter GETH\/GELTAMO study. Bone Marrow Transplant 56(8):1919\u20131928. https:\/\/doi.org\/10.1038\/s41409-021-01264-3","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5677_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","volume":"16","author":"A Sirvent","year":"2010","unstructured":"Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al (2010) Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Biol Blood Marrow Transplant 16(1):78\u201385. https:\/\/doi.org\/10.1016\/j.bbmt.2009.09.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"5677_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H et al (2018) Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 124(8):1733\u20131742. https:\/\/doi.org\/10.1002\/cncr.31264","journal-title":"Cancer"},{"issue":"1","key":"5677_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbmt.2017.10.011","volume":"24","author":"N Epperla","year":"2018","unstructured":"Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP et al (2018) Fludarabine and busulfan versus fludarabine, cyclophosphamide, and rituximab as reduced-intensity conditioning for transplantation in follicular lymphoma. Biol Blood Marrow Transplant 24(1):78\u201385. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"5677_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.bbmt.2016.04.014","volume":"22","author":"GG Laport","year":"2016","unstructured":"Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T et al (2016) Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the blood and marrow transplant clinical trials network. Biol Blood Marrow Transplant 22(8):1440\u20131448. https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"5677_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/bmt.2013.83","volume":"48","author":"SP Robinson","year":"2013","unstructured":"Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al (2013) The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 48(11):1409\u20131414. https:\/\/doi.org\/10.1038\/bmt.2013.83","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5677_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2013.09.012","volume":"42","author":"A Evens","year":"2014","unstructured":"Evens A, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS et al (2014) Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Exp Hematol 42(1):39\u201345. https:\/\/doi.org\/10.1016\/j.exphem.2013.09.012","journal-title":"Exp Hematol"},{"issue":"12","key":"5677_CR25","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","volume":"21","author":"E Klyuchnikov","year":"2015","unstructured":"Klyuchnikov E, Bacher U, Kr\u00f6ger NM, Hari PN, Ahn KW, Carreras J et al (2015) Reduced intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biol Blood Marrow Transplant 21(12):2091\u20132099. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.028","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5677_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J et al (2018) Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant 53(5):617\u2013624. https:\/\/doi.org\/10.1038\/s41409-017-0067-3","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"5677_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00277-018-3318-5","volume":"97","author":"S Yamasaki","year":"2018","unstructured":"Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T et al (2018) Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. Ann Hematol 97(8):1445\u20131452. https:\/\/doi.org\/10.1007\/s00277-018-3318-5","journal-title":"Ann Hematol"},{"issue":"14","key":"5677_CR28","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1080\/10428194.2021.1961238","volume":"62","author":"A Arcari","year":"2021","unstructured":"Arcari A, Morello L, Vallisa D, Marcheselli L, Tecchio C, Quaglia FM et al (2021) Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. Leuk Lymphoma 62(14):3474\u20133483. https:\/\/doi.org\/10.1080\/10428194.2021.1961238","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5677_CR29","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/cancers14112673","volume":"14","author":"A Gutierrez","year":"2022","unstructured":"Gutierrez A, Bento L, Novelli S, Martin A, Gutierrez G, Salas MQ et al (2022) Allogeneic stem cell transplantation in mantle cell lymphoma; insights into its potential role in the era of new immunotherapeutic and targeted therapies: The GETH\/GELTAMO experience. Cancers (Basel) 14(11):2673. https:\/\/doi.org\/10.3390\/cancers14112673","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5677_CR30","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/annonc\/mds054","volume":"23","author":"S Le Gouill","year":"2012","unstructured":"Le Gouill S, Kr\u00f6ger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al (2012) Reduced intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23(10):2695\u20132703. https:\/\/doi.org\/10.1093\/annonc\/mds054","journal-title":"Ann Oncol"},{"issue":"4","key":"5677_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Woo Ahn K, Carreras J, Cairo MS, Fenske TS et al (2013) Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 19(4):625\u2013631. https:\/\/doi.org\/10.1016\/j.bbmt.2013.01.009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"5677_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2014","unstructured":"Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A et al (2014) Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 32(4):273\u201381. https:\/\/doi.org\/10.1200\/JCO.2013.49.2454","journal-title":"J Clin Oncol."},{"issue":"12","key":"5677_CR33","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","volume":"56","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M et al (2021) ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant 56(12):2911\u20132921. https:\/\/doi.org\/10.1038\/s41409-021-01288-9","journal-title":"Bone Marrow Transplant"},{"key":"5677_CR34","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the american society for transplantation and cellular therapy. Biol Blood Marrow Transpl 25:2305\u20132321. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Suppl 1","key":"5677_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/hon.2845","volume":"39","author":"P Dreger","year":"2021","unstructured":"Dreger P (2021) Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication? Hematol Oncol 39(Suppl 1):100\u2013103. https:\/\/doi.org\/10.1002\/hon.2845","journal-title":"Hematol Oncol"},{"key":"5677_CR36","unstructured":"Zurko JC, Ramdial J, Shadman M, Ahmed S, Szabo A, Lovino L et al (2022) Allogeneic hematopoietic cell transplantation for relapsed\/refractory large B-cell lymphoma after CAR T-cell therapy failure. Tandem Meetings 2022, Abstract 8"},{"issue":"6","key":"5677_CR37","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/bjh.17460","volume":"193","author":"B Dholaria","year":"2021","unstructured":"Dholaria B, Savani BN, Huang XJ, Nagler A, Perales MA, Mohty M et al (2021) The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. Br J Haematol 193(6):1060\u20131075. https:\/\/doi.org\/10.1111\/bjh.17460","journal-title":"Br J Haematol"},{"key":"5677_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01949-x","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Bento L, Bastos-Oreiro M, Sansalvador BR, Albo C, Bailen R et al (2023) Role of allogeneic hematopoietic cell transplant for relapsed\/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-023-01949-x","journal-title":"Bone Marrow Transplant."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05677-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05677-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05677-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T02:04:35Z","timestamp":1712887475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05677-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5677"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05677-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"SM has received honoraria from Roche, Gilead, Janssen, Servier and research fundings from Roche.AM has received honoraria from Takeda; consultancy from BMS, Jazz Pharmaceuticals and research funding from Gilead.CJL has received honoraria for educational activities and\/or consultancy and\/or participation in advisory boards from Jazz, Incyte, Fresensius Kabi, BMS, Kite, Kadmon, CareDx; has received research funding from Incyte; serves on a trial steering committee for Incyte.AS has received honoraria from Takeda, BMS\/Celgene, MSD,\u00a0Janssen, Amgen,\u00a0Novartis, Gilead\u00a0Kite, Sanofi, Roche,\u00a0Alexion; consultancy from Takeda, BMS\/Celgene,\u00a0Novartis,\u00a0Janssen, Gilead, Sanofi; speaker\u2019s\u00a0Bureau from Takeda and research\u00a0support from\u00a0Takeda, BMS\/Celgene.CA, SO, EP and DRC declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}